Clinical and Molecular Features of Oral Premalignancy and Oral Cancer

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06550050
Status
Recruiting
Apply to this trial

Conditions

  • Oral Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Radiation — BEHAVIORAL
    Standard of care

Study Details

Investigators will employ serial assessments of tissue biopsy and additional biomarkers that reflect burden of disease and predict treatment response. Patients enrolled on this study will be given the option to provide biological samples before, during, and after treatment, as well as functional outcomes of treatment response. These samples will be utilized to develop and validate prognostic and predictive biomarkers for patients undergoing targeted therapy, immunotherapy, surgery, chemotherapy, and/or radiotherapy.

Key Dates

Start date
Oct 31, 2024
Status verified
Apr 2026
Primary completion
Dec 31, 2064
Completion
Dec 31, 2066

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Clinical and molecular features of oral premalignancy and oral cancer

Primary Outcome Measure

MD Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) [ Time Frame: up to 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Xiao Zhao, MD
[email protected]
713-679-8704
Xiao Zhao, MD
[email protected]
(713) 679-8704

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies